Skip to content

The Therapeutic Efficacy of Neurofeedback in Depression

The Therapeutic Efficacy of Frontal EEG Asymmetry Neurofeedback in Depression

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00729547
Acronym
neurofeedback
Enrollment
24
Registered
2008-08-07
Start date
2006-09-30
Completion date
2007-01-31
Last updated
2008-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Keywords

Depression, Biofeedback, Psychophysiology

Brief summary

The investigators examined the therapeutic efficacy of neurofeedback in depression subjects. The investigators hypothesize that 5 weeks neurofeedback training will be able to alleviate depressive symptoms.

Detailed description

Subject * Fulfilled DSM-IV criteria for depressive disorders. * Persons who had organic disorders were excluded. * Who had been treated by psychoactive drugs for at least 2 months prior to the study were excluded. Design * Subjects were randomly assigned to two groups (EEG biofeedback /psychotherapy placebo) by block randomization. * EEG biofeedback training was provided for 5 weeks(10 sessions, twice per week). Each training session was composed of 6 four minute trials followed by 5 thirty second rest periods * Psychotherapy placebo session was provided for 5 weeks. These sessions consisted of additional assessment, interpretation of the test results and providing information on course and treatment of mood disorder. * After subjects completed the training, they participated in a month-long (twice per week) self-training session to maintain a similar mental state during neurofeedback training sessions without feedback system's assistance. * Subjects who had finished the psychotherapy placebo were referred to other therapists as necessary.

Interventions

BEHAVIORALNeurofeedback

enhance relative activity level of left frontal activity

BEHAVIORALPsychotherapy placebo

These sessions consisted of additional assessment, interpretation of the test results and providing information on course and treatment of mood disorder.

Sponsors

Korea Research Foundation
CollaboratorOTHER
Kyunghee University
CollaboratorOTHER
Korea University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* clinical diagnosis of mood disorder * right handed * current BDI-2 score exceed 10

Exclusion criteria

* with psychotic symptom * with organic disorders * treated by psychoactive drugs for at least 2 months prior to the study * history of pathologic alcohol use

Design outcomes

Primary

MeasureTime frame
frontal EEG asymmetry indexes5 weeks

Secondary

MeasureTime frame
BDI-25 weeks

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026